BACKGROUND: @entity551 is common after spinal anesthesia for cesarean delivery. There is wide variability in the incidence and severity of @entity551 and in the response to treatment. The @entity2162 ( @entity2162 ) possesses several polymorphic sites. Codons 16 ( @entity25836 ) and 27 ( @entity66950 ) have been shown to affect desensitization of the receptor. The goal of this study was to determine whether genetic variants of the @entity2162 alter incidence of @entity551 or the amount of vasopressor treatment required during spinal anesthesia for cesarean delivery. METHODS: One hundred seventy healthy @entity1 undergoing elective cesarean delivery were studied. Spinal anesthesia was performed with 12 mg hyperbaric @entity1341 , 25 microg @entity3575 , and 200 microg @entity1286 . @entity551 was treated with @entity6358 and/or @entity2647 intravenously, and @entity2162 genotype at codons 16 and 27 was determined. Analysis of variance was used to compare variables between genotypes, with data expressed as mean +/- SD. RESULTS: @entity6358 or @entity2647 was used in more than 90% of @entity1 , with no difference in the incidence of @entity551 between @entity2162 genotypes. However, there was a significant effect of genotype on the amount of vasopressor required. @entity4022 16 homozygotes received significantly less @entity6358 (18 +/- 14 mg) than @entity534 16 homozygotes (28 +/- 13 mg) and @entity25836 heterozygotes (30 +/- 20 mg; P = 0.0005). @entity367 27 homozygotes required significantly less @entity6358 than @entity7647 27 homozygotes (14 +/- 13 vs. 30 +/- 19 mg; P = 0.002). @entity53941 heterozygotes received less @entity6358 than @entity7647 27 homozygotes (23 +/- 16 vs. 30 +/- 19 mg; P = 0.03). CONCLUSIONS: Glycine at position 16 and/or @entity2227 at position 27 of the @entity2162 leads to lower vasopressor use for treatment of @entity551 during spinal anesthesia.

XXXX genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity2162 :: ('154', 'Gene') :: ['beta2AR', 'beta2 adrenoceptor'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity6358 :: ('MESH:D004809', 'Chemical') :: ['ephedrine', 'Ephedrine'] @entity66950 :: ('p|SUB|E|27|Q', 'ProteinMutation') :: ['Glu27Gln'] @entity53941 :: ('p|SUB|Q|27|E', 'ProteinMutation') :: ['Gln27Glu'] @entity4022 :: ('MESH:C066286', 'Chemical') :: ['Gly'] @entity534 :: ('CHEBI:16467', 'Chemical') :: ['Arg'] @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine'] @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl'] @entity2647 :: ('MESH:D010656', 'Chemical') :: ['phenylephrine'] @entity7647 :: ('CHEBI:32668', 'Chemical') :: ['Gln'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine'] @entity367 :: ('CHEBI:18237', 'Chemical') :: ['Glu'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension', 'Maternal hypotension', 'Hypotension'] @entity25836 :: ('p|SUB|R|16|G', 'ProteinMutation') :: ['Arg16Gly']
@entity2162 :: (154,Gene) :: ['beta2-adrenoceptor']
